Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is a feasibility study of a multi-component intervention to enhance healthy living among young people with psychotic disorders, specifically targeting smoking and weight.
| Condition | Intervention | Phase |
|---|---|---|
|
Psychotic Disorder Obesity Behavior, Addictive |
Drug: nicotine transdermal patch/lozenge |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study |
- Smoking Cessation
- Body Mass Index
| Enrollment: | 43 |
| Study Start Date: | February 2007 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
We propose a feasibility study of a multi-component intervention to enhance healthy living among young people (18 to 40 years) with psychotic disorders, specifically targeting smoking and weight. Smoking is very common amongst people with psychotic disorders (around 70% of males, and over 50% of females) and this adds to the overall cardiovascular risk for this group. Obesity is also a common problem for people with psychosis, with an estimated 40-60% being obese or overweight. Obesity in this population may contribute to adverse medical and psychological consequences. For many obese people, targeted pharmacotherapy in addition to diet and increased physical activity can assist in both weight reduction and the maintenance of gains. Similarly, smoking cessation is enhanced by use of adjunctive medications such as nicotine replacement; such strategies continue to produce abstinence rates for up to 10 years.
The proposed study will assess the feasibility of a multi-component behavioural intervention focussing on smoking cessation/diet/physical activity.
The primary outcome measures from the feasibility study are smoking cessation and reduction in body mass index (BMI). Secondary outcomes will include tolerability and safety, as well as the impact the package has on other cardiovascular risk factors including serum lipids, blood sugar levels and depression in young people with psychosis. We will also establish whether smoking cessation and reduction in obesity is correlated with gains in terms of body image, quality and enjoyment of life and reduction in depression. Based on published data, behavioural interventions for smoking cessation and diet and physical activity lead smoking cessation in 20% of people at 12 months and to modest weight loss (around 5%).
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18-40 yrs
- DSM-IV diagnosis of non-organic psychotic illness
- Obesity (BMI > 30 or 27 if co-morbidities such as diabetes, hypertension or dyslipidaemia are present
- Current smoker ( > 15 cigarettes per day) if also smoking cannabis regularly, they will still be able to participate
Exclusion Criteria:
- Medical contraindication to exercise or use of the nicotine patch
- Intellectual disability that would significantly impair ability to participate in the program
- Inability to give informed consent (acutely psychotic potential participants will be reassessed one month post screening
Contacts and Locations| Australia, New South Wales | |
| Centre for Mental Health Studies, Univeristy Of Newcastle | |
| Newcastle, New South Wales, Australia, 2308 | |
| School of Public Health and Community Medicine, University of New South Wales | |
| Sydney, New South Wales, Australia, 2052 | |
| Australia, Victoria | |
| Mental Health Research Institute, University of Melbourne, Royal Melbourne Hospital | |
| Melbourne, Victoria, Australia, 3004 | |
| Department of Psychiatry, Monash University, The Alfred Hospital | |
| Melbourne, Victoria, Australia, 3004 | |
| Principal Investigator: | Amanda Baker, Assoc Prof | Centre for Mental Health Studies, Uni of Newcastle |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00350311 History of Changes |
| Other Study ID Numbers: | 95/05 |
| Study First Received: | July 6, 2006 |
| Last Updated: | September 25, 2008 |
| Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
Additional relevant MeSH terms:
|
Mental Disorders Obesity Psychotic Disorders Behavior, Addictive Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Schizophrenia and Disorders with Psychotic Features Compulsive Behavior Impulsive Behavior |
Nicotine Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 19, 2013